INmune Bio, Inc. (INMB) Misses Q2 EPS by 65c

INmune Bio, Inc. (NASDAQ: INMB) reported Q2 EPS of ($1.05), $0.65 worse than the analyst estimate of ($0.40).

For earnings history and earnings-related data on INmune Bio, Inc. (INMB) click here.

You May Also Be Interested In

• SanDisk stock target lifted at Bernstein to $3000 on new memory LTAs
• Chip stocks hit record 19.7% of S&P 500, quadrupling since 2020
• Klim and Research Frontiers strike smart glass licensing deal